Scholarlink

<p>Mitochondrial markers help stratify Parkinson’s disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Methodological validation of Miro1 retention as a candidate Parkinson’s disease biomarker

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月15日

查看全文
  • Layla Drwesh,
  • Giuseppe Arena,
  • Daniel J. Merk,
  • Daniele Ferrante,
  • Vyron Gorgogietas,
  • Thomas Gasser,
  • Anne Grünewald,
  • Patrick May,
  • Kathrin Brockmann,
  • Rejko Krüger,
  • Richard Wüst,
  • Christian Johannes Gloeckner,
  • Julia C. Fitzgerald

摘要

Mitochondrial markers help stratify Parkinson’s disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.